Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
New Approaches to Vaccine Development and Delivery—2nd Edition
share announcement

New Approaches to Vaccine Development and Delivery—2nd Edition

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Design, Development, and Delivery".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 1476

Special Issue Editors

Dr. Antonio Carlos de Freitas

E-Mail Website
Guest Editor
Laboratory of Molecular Studies and Experimental Therapy, Department of Genetics, Federal University of Pernambuco, Recife, Brazil
Interests: molecular biology of papillomavirus infections; development of vaccination strategies; control of papilomaviroses and associated diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Anna Silva

E-Mail Website
Guest Editor
Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil
Interests: oncogenes cancer research; immunology; cell biology; HPV
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent breakthroughs in immunology, protein engineering and genetic delivery have opened doors to innovative vaccine approaches that were once unattainable. These advanced designs demonstrate potential for targets where traditional methods have been ineffective. Modern strategies, including nucleic acid vaccines, whole-cell vaccines, novel delivery techniques and shelf-stable formulations, are paving new paths in both preventive and therapeutic vaccines. In this Special Issue, we will examine recent developments in vaccine technologies and delivery systems that could expand the field's possibilities.

Dr. Antonio Carlos de Freitas
Dr. Anna Silva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines and delivery
  • vaccine formulation
  • vaccine delivery systems
  • adjuvants

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

32 pages, 3556 KB  
Article
Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach
by Lígia Rosa Sales Leal, Matheus Gardini Amâncio Marques de Sena, Maria da Conceição Viana Invenção, Ingrid Andrêssa de Moura, André Luiz Santos de Jesus, Georon Ferreira de Sousa, Bárbara Rafaela da Silva Barros, Cristiane Moutinho Lagos de Melo, Lindomar José Pena, Francesca Paolini, Aldo Venuti, Anna Jéssica Duarte Silva and Antonio Carlos de Freitas
Vaccines 2026, 14(1), 31; https://doi.org/10.3390/vaccines14010031 - 26 Dec 2025
Viewed by 1171
Abstract
Background/Objectives: The Zika virus (ZIKV) represents an ongoing threat to public health due to its neurological and congenital complications. Even after 10 years since the first major outbreak, correlated with an increase in congenital ZIKV syndrome, there is still no vaccine or treatment [...] Read more.
Background/Objectives: The Zika virus (ZIKV) represents an ongoing threat to public health due to its neurological and congenital complications. Even after 10 years since the first major outbreak, correlated with an increase in congenital ZIKV syndrome, there is still no vaccine or treatment for this infection. Among the various existing platforms, DNA vaccines combined with the use of immunoinformatics tools allow for the efficient selection of immunogenic epitopes and immunostimulatory molecules with greater flexibility, in addition to being simple to manufacture and having a higher cost–benefit ratio in production. Methods: In this work, we conducted an integrated approach, combining in silico analyses and in vivo experimental validations, for the development of multi-epitope DNA vaccines against ZIKV. The computational analyses confirmed structural stability, adequate solubility, absence of toxicity, and immune induction potential for constructs based on epitopes from the Envelope (E) and NS1 proteins. Therefore, we evaluated DNA constructs containing the ENV + NS1 epitopes, both with and without fusion to the ssPGIP signal peptide, in BALB/c mice. Results: Both vaccines increased the population of CD4+ and CD8+ T lymphocytes, in addition to the production of IgG antibodies associated with the Th1 profile. The fusion with ssPGIP broadened the response, stimulating the release of Th1, Th2, and Th17 cytokines, as well as enhancing antibody formation. In contrast, its absence was associated with a slight increase in CD4+ and CD8+ T cells, accompanied by restricted cytokine production. Conclusions: These results indicate that epitope-targeted techniques offer a viable and safe method for inducing robust immune responses, demonstrating that combining immunoinformatics methods with early preclinical testing is an effective strategy for ZIKV vaccine development. Furthermore, although the present study focused on initial immunogenic characterization, future studies involving viral challenge in a suitable animal model will be essential to conclusively determine the protective efficacy of these vaccine candidates. Full article
(This article belongs to the Special Issue New Approaches to Vaccine Development and Delivery—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop